<DOC>
	<DOCNO>NCT00748410</DOCNO>
	<brief_summary>This study involve use new compound , SB-656933 . Accumulation inflammatory white blood cell ( mostly polymorphonuclear neutrophil ) gut ( colon ) may contribute pathology ulcerative colitis . It show SB-656933 reduces polymorphonuclear neutrophil ( PMN ) accumulation pre-clinical model colitis . 99m-Tc-HMPAO scintigraphy imaging technique use study observe effect SB656933 migration PMN inflame tissue .</brief_summary>
	<brief_title>Study Evaluate Pharmacodynamics SB-656933 Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Inclusion criterion : A history ulcerative colitis least 3 month moderately active UC , either stable medication flare disease Mayo endoscopic score 2 3 within 2 day dose . Male female 18 65 year age Women child bear potential must use effective method contraception . Male subject must agree use one specified contraception method , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) normal study start . Signed write informed consent QTcB QTcF &lt; 450msec screen Exclusion criterion : The subject positive prestudy drug/alcohol screen . A positive test HIV , hepatitis B C. History regular alcohol consumption within 6 month study Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day 5 halflives prior first dose study medication Known allergy recent participation another trial recent blood donation Pregnant lactating female unwillingness inability follow study procedure consumption red wine , seville orange , grapefruit grapefruit juice last 7 seven day study start . Mild UC , Mayo endoscopic score 0 1 . Toxic megacolon perforation plain abdominal Xray . Crohn 's Disease , indeterminate colitis , bleed disorder , active ulcer disease . Previous colonic surgery . Current recurrent disease , UC , could affect action , absorption disposition study medication , clinical laboratory assessment . Absolute neutrophil count 2.0x109/L . A positive culture enteric pathogen clinically significant , presence clostridium difficile toxin , ova parasite detect microscopy , clinical suspicion infectious disease bowel . Symptomatic GI stricture within 6 month screen obstructive symptom within 3 month screen . Likely require abdominal surgery within study period . Congenital acquire immunodeficiency , include immunologic disease gastrointestinal involvement except UC . Ongoing neoplastic disease bowel . History prostatitis , epididymitis , epididymal cyst , structural abnormality testicular cancer . Subjects abnormalities renal tract , renal stone history recurrent urinary tract infection ( UTI.s ) . Subjects history autoimmune hepatitis sclerosing cholangitis . Previous inclusion research and/or medical protocol involve nuclear medicine , PET radiological investigation significant radiation burden . Blood pressure persistently â‰¥ 140/90 mmHg screen Concurrent illness disability may affect interpretation clinical data , otherwise contraindicate participation clinical study ( e.g. , unstable cardiovascular , autoimmune , renal , pulmonary , hepatic , endocrine , metabolic , haematological , neurological condition ) . Clinically significant hepatic impairment ( Evidence cirrhosis , Clinical episode jaundice ) Current evidence , treat malignancy within past 5 year . BMI &lt; 18 kg.m2 &gt; 35 kg/m2 Clinically significant renal laboratory value . Has discontinue prohibit concomitant medication prior screen visit within protocolspecified time period . Has remain stable dose permit concomitant medication ( ) protocolspecified time period precede Screening Visit . history substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CD11b</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>99mTc-HMPAO-labelled leukocyte scintigraphy</keyword>
</DOC>